Professional Documents
Culture Documents
BREAST
SOLUTIONS
HEALTH
Ergonomic, motorized height adjustment feature. Acquisition of 15 projection images (1 image/degree of arc) and filtered back reconstruction
enable rapid reconstruction of high quality images.
Your choice of paddles, accessories and license options.
40%
reduction in
radiation dose compared to standard 2D imaging.6
recall rates3,5
Hologic 3D mammography. The only system with proven superior C-View software brilliantly reconstructs highly detailed
clinical performance.1-3 2D breast images from a 3D tomosynthesis data set.
With a quick and easy transition from mammography to upright biopsy, the Affirm system offers a cost-effective,
space-saving and upgradeable system that enables practices to expand their range of service offerings.
A comprehensive
solution
Efficient and interactive diagnostic tools
A full range of workflow solutions, customizable
to your needs.
References: 1. Skaane P, Bandos A, Gullien R, et al. Comparison of Digital Mammography Alone and Digital Mammography Plus Tomosynthesis in a Population-based Screening Program. Radiology. 2013
Apr; 267(1):47-56. Epub 2013 Jan 7. 2. Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D Digital Mammography With Tomosynthesis for Population Breast-Cancer Screening (STORM): A Prospective
Comparison Study The Lancet Oncology. 2013 Jun;14(7):583-589. Epub 2013 Apr 25. 3. Rose S, Tidwell A, Bujnock L, et al. Implementation of Breast Tomosynthesis in a Routine Screening Practice: An
Observational Study. American Journal of Roentengenology. 2013 Jun; 200(6): 1401-1408. Epub 2013 May 22. 4. Zuley M, Bandos A, Ganott M, et al. Digital Breast Tomosynthesis Versus Supplemental
Diagnostic Mammographic Views for Evaluation of Noncalcified Breast Lesions. Radiology. 2013 Jan; 266(1):89-95. Epub 2012 Nov 9. 5. Haas B, Kalra V, Geisel J et al. Comparison of Tomosynthesis Plus
Digital Mammography and Digital Mammography Alone for Breast Cancer Screening. Radiology. 2013 July 30. [Epub ahead of print]. 6. FDA PMA submission P080003/S001. Based on the U.S. average dose
of FFDM, S/F and CR as collected from medical physicists dose measurements available at the time of MQSA inspections Jan Sept 2012.
Preserving Lives. At Hologic, we deliver trailblazing technologies to keep you on the forefront of breast care.
Our passion drives us in the relentless pursuit of innovative tools that set new paradigms for the early detection,
accurate diagnosis, intervention and treatment of breast cancer technologies to help you protect and preserve
the lives of your patients. With you, we are on a mission to help women live longer, healthier lives.
PB-00123-002 (11/13) US/International Hologic 2013. All rights reserved. Printed in USA. Specifications are subject to change without prior notice. Hologic, Affirm, Dimensions,
Eviva, FAST Paddle, SecurView, Selenia, Smart Paddle and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States
and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such
activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear.
For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com.